Depigoid Parietaria judaica 1000DPP/ml — Competitive Intelligence Brief

Depigoid Parietaria judaica 1000DPP/ml (Depigoid Parietaria judaica 1000DPP/ml) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Allergen immunotherapy extract. Area: Immunology / Allergy.

phase 3 Allergen immunotherapy extract Immunology / Allergy Biologic

Target snapshot

Depigoid Parietaria judaica 1000DPP/ml (Depigoid Parietaria judaica 1000DPP/ml) — Laboratorios Leti, S.L.. Depigoid is an allergen extract-based immunotherapeutic that desensitizes the immune system to Parietaria judaica pollen through gradual exposure, reducing allergic responses.

Comparator set (3 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Depigoid Parietaria judaica 1000DPP/ml TARGET	Depigoid Parietaria judaica 1000DPP/ml	Laboratorios Leti, S.L.	phase 3	Allergen immunotherapy extract
PURETHAL Birch, 20.000 AUM/ml	PURETHAL Birch, 20.000 AUM/ml	HAL Allergy	marketed	Allergen immunotherapy extract	Birch pollen allergens (Bet v 1 and related proteins)
PURETHAL Grasses, 20.000 AUM/ml	PURETHAL Grasses, 20.000 AUM/ml	HAL Allergy	marketed	Allergen immunotherapy extract	Grass pollen allergens (IgE and T-cell epitopes)
GRASS 2800 BAU	GRASS 2800 BAU	Clinique Spécialisée en Allergies de la Capitale	marketed	Allergen immunotherapy extract	Grass pollen allergens (Poa pratensis, Lolium perenne, and other grass species)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Allergen immunotherapy extract class)

1. HAL Allergy · 2 drugs in this class
2. Clinique Spécialisée en Allergies de la Capitale · 1 drug in this class
3. Laboratorios Leti, S.L. · 1 drug in this class